PMID- 25773816
OWN - NLM
STAT- MEDLINE
DCOM- 20160126
LR  - 20190606
IS  - 2476-762X (Electronic)
IS  - 1513-7368 (Linking)
VI  - 16
IP  - 5
DP  - 2015
TI  - Effect of paclitaxel-loaded nanoparticles on the viability of human 
      hepatocellular carcinoma HepG2 cells.
PG  - 1725-8
AB  - OBJECTIVE: To explore effects of paclitaxel-loaded poly lactic-co-glycolic acid 
      (PLGA) particles on the viability of human hepatocellular carcinoma (HCC) HepG2 
      cells. MATERIALS AND METHODS: The viability of HepG2 cells was assessed using MTT 
      under different concentrations of prepared paclitaxel-loaded particles and 
      paclitaxel (6.25, 12.5, 25, 50, and 100 mg/L), and apoptosis was analyzed using 
      Hochest33342/Annexin V-FITC/PI combined with an IN Cell Analyzer 2000. RESULTS: 
      Paxlitaxel-loaded nanoparticles were characterized by narrow particle size 
      distribution (158.6 nm average particle size). The survival rate of HepG2 cells 
      exposed to paclitaxel-loaded PLGA particles decreased with the increase of 
      concentration and time period (P<0.01 or P<0.05), the dose- and time-dependence 
      indicating sustained release (P<0.05). Moreover, apoptosis of HepG2 cells was 
      induced, again with an obvious dose- and time-effect relationship (P<0.05). 
      CONCLUSIONS: Paclitaxel-loaded PLGA particles can inhibit the proliferation and 
      induce the apoptosis of HCC HepG2 cells. This new-type of paclitaxel carrier body 
      is easily made and has low cost, good nanoparticle characterization and sustained 
      release. Hence, paclitaxel- loaded PLGA particles deserve to be widely 
      popularized in the clinic.
FAU - Hou, Zhi-Hong
AU  - Hou ZH
AD  - Pharmacy Department, The 208th Hospital of PLA., Changchun, China E-mail : 
      zqi8229@126.com.
FAU - Zhao, Wen-Cui
AU  - Zhao WC
FAU - Zhang, Qi
AU  - Zhang Q
FAU - Zheng, Wei
AU  - Zheng W
LA  - eng
PT  - Journal Article
PL  - Thailand
TA  - Asian Pac J Cancer Prev
JT  - Asian Pacific journal of cancer prevention : APJCP
JID - 101130625
RN  - 0 (Antineoplastic Agents, Phytogenic)
RN  - 0 (Drug Carriers)
RN  - 1SIA8062RS (Polylactic Acid-Polyglycolic Acid Copolymer)
RN  - 26009-03-0 (Polyglycolic Acid)
RN  - 33X04XA5AT (Lactic Acid)
RN  - P88XT4IS4D (Paclitaxel)
SB  - IM
MH  - Antineoplastic Agents, Phytogenic/therapeutic use
MH  - Apoptosis/drug effects
MH  - Carcinoma, Hepatocellular/*drug therapy
MH  - Cell Line, Tumor
MH  - Cell Proliferation/drug effects
MH  - Cell Survival/drug effects
MH  - Drug Carriers/*therapeutic use
MH  - Hep G2 Cells
MH  - Humans
MH  - Lactic Acid/therapeutic use
MH  - Liver Neoplasms/*drug therapy
MH  - Nanoparticles/*therapeutic use
MH  - Paclitaxel/*therapeutic use
MH  - Polyglycolic Acid/therapeutic use
MH  - Polylactic Acid-Polyglycolic Acid Copolymer
EDAT- 2015/03/17 06:00
MHDA- 2016/01/27 06:00
CRDT- 2015/03/17 06:00
PHST- 2015/03/17 06:00 [entrez]
PHST- 2015/03/17 06:00 [pubmed]
PHST- 2016/01/27 06:00 [medline]
AID - 10.7314/apjcp.2015.16.5.1725 [doi]
PST - ppublish
SO  - Asian Pac J Cancer Prev. 2015;16(5):1725-8. doi: 10.7314/apjcp.2015.16.5.1725.